

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Union Medical Healthcare Limited

香港醫思醫療集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

INSIDE INFORMATION SALES VOLUME UPDATE

This announcement is made by Union Medical Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Sales volume for October to December 2020

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to further inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited management accounts of the Group for the period from 1 October 2020 to 31 December 2020 (the “**Quarter**”) currently available, the Group expects to record:

- (i) a sales volume (being the total sales volume generated from contracted sales entered into, and all products and services offered by the Group, the “**Sales Volume**”) of no less than HK\$600 million for the Quarter, representing an increase of no less than 10% as compared with the same period last year and an increase of no less than 25% as compared with the three months ended 30 September 2020;
- (ii) an increase in Sales Volume in those clinics and service centers located in Mainland China of no less than 35% for the Quarter as compared with the same period last year and an increase of no less than 45% as compared with the three months ended 30 September 2020; and
- (iii) an increase in Sales Volume of medical services offered by the Group of no less than 50% for the Quarter as compared with the same period last year and an increase of no less than 10% as compared with the three months ended 30 September 2020.

Summarized as below:

Three months ended	Year-on-Year growth	Quarter-on-Quarter growth
31 December 2020	No less than	No less than
Overall Sales Volume	10%	25%
Sales Volume in Mainland China	35%	45%
Sales Volume of medical services	50%	10%

Despite the adverse economic conditions resulting from the outbreak of COVID-19 with continuous travel restrictions, social distancing and another round of compulsory closure of all beauty parlors in Hong Kong since 10 December 2020, the Group was able to redirect its proactive client engagement and e-commerce campaigns to boost sales in local spending and Mainland China, and complete acquisitions of certain medical establishments during the Quarter. The Board is of the view that the overall operation and financial position of the Group remain sound and healthy.

Looking ahead, the Group is optimistic about its business performance in the coming quarters. The Group will closely monitor the coming COVID-19 vaccination scheme by the Hong Kong Government and continue to develop our business, with particular focus on information technology, brand and service, while complying with the relevant rules and regulations.

The Board wishes to remind Shareholders and potential investors that the above data are based on the unaudited management accounts of the Group which have not been reviewed or audited by the auditors of the Company. Sales performance during the Quarter are affected by a series of factors, and, the operational data for the Quarter may not be able to reflect the overall performance for a complete Quarter.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Union Medical Healthcare Limited
Raymond Siu
Company Secretary

Hong Kong, 21 January 2021

As at the date of this announcement, the board of Directors comprises four executive Directors, namely Mr. Tang Chi Fai, Mr. Lee Gabriel, Mr. Lee Heung Wing and Mr. Wong Chi Cheung; two non-executive Directors, namely Mr. Luk Kun Shing Ben and Dr. Wang Steven Dasong, and three independent non-executive Directors, namely Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.

**For identification purpose only.*